Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654314 · ClinicalTrials.gov registry record · Phase 3
Prevention of Delirium in Inpatients Utilizing Melatonin
A Phase 3 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 277
- Enrollment target
NCT02654314: Clinical Trial Phase 3 study, sponsored by Yale University.
NCT02654314 is a Phase 3 study that was terminated before completion, run by Yale University. The registered enrollment target is 277 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02654314, a Phase 3 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 277 participants
- Enrollment target
Study Summary
A double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo, given to patients at least 65 years old, admitted to the hospital on a general medical floor, to prevent delirium.
Primary Outcome
Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization.
Interventions
- OTHER Placebo
- DRUG Melatonin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-11-03 |
| Phase | Phase 3 |
Why NCT02654314 stopped before completion
NCT02654314 is an interventional study that assigns participants to a tested intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02654314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02654314 about?
NCT02654314 is a clinical study titled "Prevention of Delirium in Inpatients Utilizing Melatonin". A double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo, given to patients at least 65 years old, admitted to the hospital on a general medical floor, to prevent delirium.
What is the current status of trial NCT02654314?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 277 participants. The study started on 2016-07. Estimated completion is 2017-11-03.
What interventions are being tested in trial NCT02654314?
The interventions under investigation include: Placebo (OTHER), Melatonin (DRUG).
Who is sponsoring clinical trial NCT02654314?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02654314's enrollment target sits among peer trials
277 1202nd of 2000 higher than 799 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia